Analysts with RBC Capital have increased their price target of Boston Scientific to $20, according to a report by The Legacy.
RBC Capital rated the company's stock at "outperform." Boston Scientific stock has a 52-week high of $18.40 and a 52-week low of $11.10, according to the report.